IRVINE, CA and SAN DIEGO, CA--(Marketwire - November 10, 2008) - Edwards Lifesciences Corporation (NYSE: EW), a global leader in the monitoring of critically ill patients, and DexCom, Inc. (NASDAQ: DXCM), a developer and marketer of home-based continuous glucose monitoring systems for patients with diabetes, have entered into a definitive collaboration agreement to develop products for continuously monitoring blood glucose levels in patients hospitalized for a variety of conditions. The agreement provides Edwards with an exclusive license to all of DexCom’s applicable intellectual property.
